Published in J Diabetes Sci Technol on May 01, 2007
In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol (2009) 5.24
Artificial pancreas: past, present, future. Diabetes (2011) 3.03
Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol (2009) 2.67
Evaluating the efficacy of closed-loop glucose regulation via control-variability grid analysis. J Diabetes Sci Technol (2008) 2.24
Diabetes: Models, Signals, and Control. IEEE Rev Biomed Eng (2009) 2.11
Impact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study. J Diabetes Sci Technol (2010) 1.99
Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol (2009) 1.63
Analysis, modeling, and simulation of the accuracy of continuous glucose sensors. J Diabetes Sci Technol (2008) 1.51
Challenges and Recent Progress in the Development of a Closed-loop Artificial Pancreas. Annu Rev Control (2012) 1.49
Run-to-run tuning of model predictive control for type 1 diabetes subjects: in silico trial. J Diabetes Sci Technol (2009) 1.23
In silico preclinical trials: methodology and engineering guide to closed-loop control in type 1 diabetes mellitus. J Diabetes Sci Technol (2009) 1.19
Linear quadratic gaussian-based closed-loop control of type 1 diabetes. J Diabetes Sci Technol (2007) 1.16
Physical activity into the meal glucose-insulin model of type 1 diabetes: in silico studies. J Diabetes Sci Technol (2009) 1.13
Modeling the error of continuous glucose monitoring sensor data: critical aspects discussed through simulation studies. J Diabetes Sci Technol (2010) 1.02
Diabetes technology: markers, monitoring, assessment, and control of blood glucose fluctuations in diabetes. Scientifica (Cairo) (2012) 0.95
Effects of pulsatile subcutaneous injections of insulin lispro on plasma insulin concentration levels. J Diabetes Sci Technol (2008) 0.94
In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. Diabetes Technol Ther (2013) 0.92
Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients. Diabetes Technol Ther (2013) 0.90
Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator. Diabetes Technol Ther (2016) 0.85
Systematically in silico comparison of unihormonal and bihormonal artificial pancreas systems. Comput Math Methods Med (2013) 0.82
Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes. J Diabetes Sci Technol (2016) 0.81
Higher accuracy of self-monitoring of blood glucose in insulin-treated patients in Germany: clinical and economical aspects. J Diabetes Sci Technol (2013) 0.81
Data-driven health management: reasoning about personally generated data in diabetes with information technologies. J Am Med Inform Assoc (2016) 0.79
Anticipating the next meal using meal behavioral profiles: a hybrid model-based stochastic predictive control algorithm for T1DM. Comput Methods Programs Biomed (2010) 0.79
The next generation of artificial pancreas control algorithms. J Diabetes Sci Technol (2008) 0.79
How Much Is Short-Term Glucose Prediction in Type 1 Diabetes Improved by Adding Insulin Delivery and Meal Content Information to CGM Data? A Proof-of-Concept Study. J Diabetes Sci Technol (2016) 0.79
Switched LPV Glucose Control in Type 1 Diabetes. IEEE Trans Biomed Eng (2015) 0.78
In silico Models of Alcohol Dependence and Treatment. Front Psychiatry (2012) 0.77
Multilevel model of type 1 diabetes mellitus patients for model-based glucose controllers. J Diabetes Sci Technol (2013) 0.76
A computational proof of concept of a machine-intelligent artificial pancreas using Lyapunov stability and differential game theory. J Diabetes Sci Technol (2014) 0.75
Pharmacokinetic Model of the Transport of Fast-Acting Insulin From the Subcutaneous and Intradermal Spaces to Blood. J Diabetes Sci Technol (2015) 0.75
Reducing Glucose Variability Due to Meals and Postprandial Exercise in T1DM Using Switched LPV Control: In Silico Studies. J Diabetes Sci Technol (2016) 0.75
A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy. Sci Rep (2016) 0.75
Glucose-responsive insulin by molecular and physical design. Nat Chem (2017) 0.75
Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes (2006) 6.52
Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas (2004) 5.65
Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng (2007) 3.54
A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther (2005) 3.28
A physiological model of glucose-insulin interaction in type 1 diabetes mellitus. J Biomed Eng (1992) 2.58
Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes (2006) 2.20
Use of a novel triple-tracer approach to assess postprandial glucose metabolism. Am J Physiol Endocrinol Metab (2003) 1.92
Insulin kinetics in type-I diabetes: continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng (2005) 1.86
A probabilistic approach to glucose prediction and insulin dose adjustment: description of metabolic model and pilot evaluation study. Comput Methods Programs Biomed (1994) 1.52
Models of subcutaneous insulin kinetics. A critical review. Comput Methods Programs Biomed (2000) 1.32
Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. Br Med J (Clin Res Ed) (1983) 1.22
Validation of mathematical models of complex endocrine-metabolic systems. A case study on a model of glucose regulation. Med Biol Eng Comput (1983) 1.14
Kinetic modeling of the glucoregulatory system to improve insulin therapy. IEEE Trans Biomed Eng (1985) 1.05
Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. J Clin Endocrinol Metab (1984) 1.05
Type I diabetes mellitus does not alter initial splanchnic glucose extraction or hepatic UDP-glucose flux during enteral glucose administration. Diabetologia (2001) 1.00
Evaluation of portal/peripheral route and of algorithms for insulin delivery in the closed-loop control of glucose in diabetes--a modeling study. IEEE Trans Biomed Eng (1983) 0.99
A mathematical model for the control mechanism of free fatty acid-glucose metabolism in normal humans. Comput Biomed Res (1970) 0.95
Glucose effectiveness and insulin sensitivity from the minimal models: consequences of undermodeling assessed by Monte Carlo simulation. IEEE Trans Biomed Eng (1999) 0.93
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 16.62
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med (2007) 6.00
In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol (2009) 5.24
Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes (2008) 5.23
Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng (2007) 3.54
Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol (2010) 3.48
Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes (2012) 3.40
Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. Diabetes (2003) 3.23
Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol (2007) 3.14
High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes (2007) 2.96
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A (2006) 2.88
Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes (2003) 2.53
Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care (2006) 2.46
Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol (2006) 2.38
Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. J Diabetes Sci Technol (2009) 2.31
Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series. IEEE Trans Biomed Eng (2007) 2.31
Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care (2013) 2.26
Evaluating the efficacy of closed-loop glucose regulation via control-variability grid analysis. J Diabetes Sci Technol (2008) 2.24
β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care (2012) 2.20
Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes (2006) 2.20
The impact of planned care and a diabetes electronic management system on community-based diabetes care: the Mayo Health System Diabetes Translation Project. Diabetes Care (2002) 2.07
Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab (2004) 2.04
Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes (2006) 2.02
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab (2007) 2.02
Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care (2006) 1.93
Use of a novel triple-tracer approach to assess postprandial glucose metabolism. Am J Physiol Endocrinol Metab (2003) 1.92
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90
The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng (2002) 1.88
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab (2007) 1.82
Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes (2004) 1.76
Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation (2006) 1.69
A system model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng (2006) 1.66
Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes (2007) 1.63
Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clin Proc (2005) 1.62
Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes (2005) 1.62
Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes. Diabetes Care (2012) 1.57
Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes (2007) 1.57
Control to range for diabetes: functionality and modular architecture. J Diabetes Sci Technol (2009) 1.55
Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system. Diabetes (2013) 1.51
Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab (2005) 1.50
Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes (2010) 1.48
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes (2007) 1.47
Diurnal pattern to insulin secretion and insulin action in healthy individuals. Diabetes (2012) 1.46
Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care (2009) 1.46
A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab (2005) 1.41
Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices. Diabetes Care (2014) 1.37
Real-time improvement of continuous glucose monitoring accuracy: the smart sensor concept. Diabetes Care (2012) 1.37
Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care (2008) 1.35
Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center. J Diabetes Sci Technol (2012) 1.35
Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab (2010) 1.34
Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes (2012) 1.32
Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care (2013) 1.32
Time lag of glucose from intravascular to interstitial compartment in humans. Diabetes (2013) 1.32
Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab (2010) 1.31
Hyperoxia blunts counterregulation during hypoglycaemia in humans: possible role for the carotid bodies? J Physiol (2010) 1.28
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) (2009) 1.27
Measurement of selective effect of insulin on glucose disposal from labeled glucose oral test minimal model. Am J Physiol Endocrinol Metab (2005) 1.25
Mechanism of insulin's anabolic effect on muscle: measurements of muscle protein synthesis and breakdown using aminoacyl-tRNA and other surrogate measures. Am J Physiol Endocrinol Metab (2006) 1.24
Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J (2008) 1.24
Assessment of postprandial glucose metabolism: conventional dual- vs. triple-tracer method. Am J Physiol Endocrinol Metab (2006) 1.24
Enhanced accuracy of continuous glucose monitoring by online extended kalman filtering. Diabetes Technol Ther (2010) 1.23
Run-to-run tuning of model predictive control for type 1 diabetes subjects: in silico trial. J Diabetes Sci Technol (2009) 1.23
Significance analysis of microarray transcript levels in time series experiments. BMC Bioinformatics (2007) 1.22
Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol (2008) 1.22
A quantization method based on threshold optimization for microarray short time series. BMC Bioinformatics (2005) 1.21
Impaired glycemia and diabetic polyneuropathy: the OC IG Survey. Diabetes Care (2012) 1.21
Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. Am J Physiol Endocrinol Metab (2004) 1.21
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care (2008) 1.20
Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care (2007) 1.20
Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab (2006) 1.18
Design, methods, and evaluation directions of a multi-access service for the management of diabetes mellitus patients. Diabetes Technol Ther (2003) 1.18
Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes (2008) 1.17
An online self-tunable method to denoise CGM sensor data. IEEE Trans Biomed Eng (2009) 1.17
Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes (2002) 1.16
Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11beta-hsd) type 1 pathway. Diabetes (2004) 1.16
Reconstruction of glucose in plasma from interstitial fluid continuous glucose monitoring data: role of sensor calibration. J Diabetes Sci Technol (2007) 1.15
Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes (2008) 1.13
Physical activity into the meal glucose-insulin model of type 1 diabetes: in silico studies. J Diabetes Sci Technol (2009) 1.13